The hormonal drug CDMO market is witnessing steady growth driven by rising demand for outsourced development and manufacturing of hormonal therapies for reproductive health, oncology, and endocrine disorders. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hormonal Drug CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hormonal Drug CDMO Market, by Molecule Type
8.1.1. Small-Molecule Steroid Hormones
8.1.1.1. Market Revenue and Forecast
8.1.2. Peptide/Protein Hormones
8.1.2.1. Market Revenue and Forecast
8.1.3. Conjugates & Modified Hormones
8.1.3.1. Market Revenue and Forecast
9.1. Hormonal Drug CDMO Market, by Service Type
9.1.1. API Development & Manufacturing (process/route scouting, scale-up)
9.1.1.1. Market Revenue and Forecast
9.1.2. Peptide Synthesis & Purification (SPPS/LPPS, HPLC)
9.1.2.1. Market Revenue and Forecast
9.1.3. HPAPI Handling & Micronization
9.1.3.1. Market Revenue and Forecast
9.1.4. Formulation Development (OSD, sterile, depot/LAI)
9.1.4.1. Market Revenue and Forecast
9.1.5. Aseptic Fill-Finish (vials, PFS, cartridges)
9.1.5.1. Market Revenue and Forecast
9.1.6. Analytical/QC & Stability
9.1.6.1. Market Revenue and Forecast
9.1.7. Packaging & Serialization
9.1.7.1. Market Revenue and Forecast
9.1.8. Tech Transfer & Validation
9.1.8.1. Market Revenue and Forecast
9.1.9. Regulatory & CMC Support
9.1.9.1. Market Revenue and Forecast
9.1.10. Others
9.1.10.1. Market Revenue and Forecast
10.1. Hormonal Drug CDMO Market, by Dosage Form / Delivery
10.1.1. Oral Solid Dose (OSD)
10.1.1.1. Market Revenue and Forecast
10.1.2. IR tablets/capsules
10.1.2.1. Market Revenue and Forecast
10.1.3. MR/controlled-release
10.1.3.1. Market Revenue and Forecast
10.1.4. Softgels
10.1.4.1. Market Revenue and Forecast
10.1.5. Parenteral
10.1.5.1. Market Revenue and Forecast
10.1.6. Implants & Rings
10.1.6.1. Market Revenue and Forecast
10.1.7. Transdermal Patches
10.1.7.1. Market Revenue and Forecast
10.1.8. Topicals (creams/gels/ointments)
10.1.8.1. Market Revenue and Forecast
10.1.9. Nasal/Sublingual/Buccal
10.1.9.1. Market Revenue and Forecast
10.1.10. Others
10.1.10.1. Market Revenue and Forecast
11.1. Hormonal Drug CDMO Market, by Therapy Area
11.1.1. Women’s Health (contraception, HRT)
11.1.1.1. Market Revenue and Forecast
11.1.2. Endocrinology & Metabolic (diabetes, thyroid, growth disorders)
11.1.2.1. Market Revenue and Forecast
11.1.3. Oncology (Hormone-Dependent)
11.1.3.1. Market Revenue and Forecast
11.1.4. Fertility & IVF
11.1.4.1. Market Revenue and Forecast
11.1.5. Inflammation/Immune (corticosteroids)
11.1.5.1. Market Revenue and Forecast
11.1.5. Urology/Andrology
11.1.5.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Molecule Type
12.1.2. Market Revenue and Forecast, by Service Type
12.1.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.1.4. Market Revenue and Forecast, by Therapy Area
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Molecule Type
12.1.5.2. Market Revenue and Forecast, by Service Type
12.1.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.1.5.4. Market Revenue and Forecast, by Therapy Area
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Molecule Type
12.1.6.2. Market Revenue and Forecast, by Service Type
12.1.6.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.1.6.4. Market Revenue and Forecast, by Therapy Area
12.2. Europe
12.2.1. Market Revenue and Forecast, by Molecule Type
12.2.2. Market Revenue and Forecast, by Service Type
12.2.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.2.4. Market Revenue and Forecast, by Therapy Area
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Molecule Type
12.2.5.2. Market Revenue and Forecast, by Service Type
12.2.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.2.5.4. Market Revenue and Forecast, by Therapy Area
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Molecule Type
12.2.6.2. Market Revenue and Forecast, by Service Type
12.2.6.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.2.6.4. Market Revenue and Forecast, by Therapy Area
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Molecule Type
12.2.7.2. Market Revenue and Forecast, by Service Type
12.2.7.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.2.7.4. Market Revenue and Forecast, by Therapy Area
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Molecule Type
12.2.8.2. Market Revenue and Forecast, by Service Type
12.2.8.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.2.8.4. Market Revenue and Forecast, by Therapy Area
12.3. APAC
12.3.1. Market Revenue and Forecast, by Molecule Type
12.3.2. Market Revenue and Forecast, by Service Type
12.3.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.3.4. Market Revenue and Forecast, by Therapy Area
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Molecule Type
12.3.5.2. Market Revenue and Forecast, by Service Type
12.3.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.3.5.4. Market Revenue and Forecast, by Therapy Area
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Molecule Type
12.3.6.2. Market Revenue and Forecast, by Service Type
12.3.6.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.3.6.4. Market Revenue and Forecast, by Therapy Area
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Molecule Type
12.3.7.2. Market Revenue and Forecast, by Service Type
12.3.7.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.3.7.4. Market Revenue and Forecast, by Therapy Area
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Molecule Type
12.3.8.2. Market Revenue and Forecast, by Service Type
12.3.8.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.3.8.4. Market Revenue and Forecast, by Therapy Area
12.4. MEA
12.4.1. Market Revenue and Forecast, by Molecule Type
12.4.2. Market Revenue and Forecast, by Service Type
12.4.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.4.4. Market Revenue and Forecast, by Therapy Area
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Molecule Type
12.4.5.2. Market Revenue and Forecast, by Service Type
12.4.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.4.5.4. Market Revenue and Forecast, by Therapy Area
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Molecule Type
12.4.6.2. Market Revenue and Forecast, by Service Type
12.4.6.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.4.6.4. Market Revenue and Forecast, by Therapy Area
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Molecule Type
12.4.7.2. Market Revenue and Forecast, by Service Type
12.4.7.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.4.7.4. Market Revenue and Forecast, by Therapy Area
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Molecule Type
12.4.8.2. Market Revenue and Forecast, by Service Type
12.4.8.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.4.8.4. Market Revenue and Forecast, by Therapy Area
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Molecule Type
12.5.2. Market Revenue and Forecast, by Service Type
12.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.5.4. Market Revenue and Forecast, by Therapy Area
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Molecule Type
12.5.5.2. Market Revenue and Forecast, by Service Type
12.5.5.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.5.5.4. Market Revenue and Forecast, by Therapy Area
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Molecule Type
12.5.6.2. Market Revenue and Forecast, by Service Type
12.5.6.3. Market Revenue and Forecast, by Dosage Form / Delivery
12.5.6.4. Market Revenue and Forecast, by Therapy Area
13.1. CordenPharma
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Siegfried
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Lonza
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Catalent
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. WuXi STA
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Piramal Pharma Solutions
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cambrex
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Almac Group
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Olon
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description